Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 0.62 |
| ▸ | CA4 | P22748 | 2/20 | 0.62 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA6 | P23280 | 1/20 | 0.57 |
| ▸ | CA5A | P35218 | 1/20 | 0.57 |
| ▸ | CA7 | P43166 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.57 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9597084 | 0.93 | CA2 (0.53) | CA2CA4CA12CA1CA6 | |
| SCHEMBL12603509 | 0.84 | CA2 (0.45) | CA2CA4CA12CA1CA6 | |
| SCHEMBL12603517 | 0.82 | CA2 (0.43) | CA2CA4CA12CA1CA6 | |
| SCHEMBL9257269 | 0.81 | CA2 (0.45) | CA2CA4CA12CA1CA6 | |
| SCHEMBL8869854 | 0.81 | CA2 (0.45) | CA2CA4CA12CA1CA6 | |
| SCHEMBL13545431 | 0.79 | CA2 (0.64) | CA2CA4CA12CA1CA6 | |
| SCHEMBL2631258 | 0.78 | CA2 (0.79) | CA2CA4CA12CA1CA6 | |
| SCHEMBL3586580 | 0.78 | CA2 (0.79) | CA2CA4CA12CA1CA6 | |
| SCHEMBL3576264 | 0.78 | CA2 (0.79) | CA2CA4CA12CA1CA6 | |
| SCHEMBL9265035 | 0.78 | CA2 (0.62) | CA2CA4CA12CA1CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210145836-A1 | PRODUCTION OF STERILE ACTIVE PHARMACEUTICAL INGREDIENTS | ICROM SPA (IT) | 2021-05-20 | — | — | US | disclosed |
| US-20210145836-A1 | PRODUCTION OF STERILE ACTIVE PHARMACEUTICAL INGREDIENTS | ICROM SPA (IT) | 2021-05-20 | — | — | US | disclosed |
| US-10953115-B2 | Production of sterile active pharmaceutical ingredients | Icrom S.R.L. (IT) | 2021-03-23 | — | — | US | disclosed |
| US-10953115-B2 | Production of sterile active pharmaceutical ingredients | Icrom S.R.L. (IT) | 2021-03-23 | — | — | US | disclosed |
| US-20180030419-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2018-02-01 | — | — | US | disclosed |
| US-20170355966-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | CODEXIS, INC. (US) | 2017-12-14 | — | — | US | disclosed |
| US-9828614-B1 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-9822346-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9803224-B2 | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds | CODEXIS, INC. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170268028-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2017-09-21 | — | — | US | disclosed |
| US-20150141412-A1 | PRODUCTION OF STERILE ACTIVE PHARMACEUTICAL INGREDIENTS | ICROM SPA (IT) | 2015-05-21 | — | — | US | disclosed |
| CN-104487099-A | Production of sterile active pharmaceutical ingredients | ICROM SPA | 2015-04-01 | — | — | CN | disclosed |
| US-8344136-B2 | Process for the preparation of brinzolamide | PHF S.A. (CH) | 2013-01-01 | — | — | US | disclosed |
| US-8344136-B2 | Process for the preparation of brinzolamide | PHF S.A. (CH) | 2013-01-01 | — | — | US | disclosed |
| US-20110118461-A1 | PROCESS FOR THE PREPARATION OF BRINZOLAMIDE | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20110118461-A1 | PROCESS FOR THE PREPARATION OF BRINZOLAMIDE | F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) | 2011-05-19 | — | — | US | disclosed |
| WO-2010004457-A2 | PROCESS FOR THE PREPARATION OF BRINZOLAMIDE | PHF SA (CH) | 2010-01-14 | — | — | WO | disclosed |
| US-5679670-A | CONTROLLING INTRAOCULAR PRESSURE | ALCON LABORATORIES, INC. (US) | 1997-10-21 | — | — | US | disclosed |
| US-5378703-A | FOR CONTROLLING INTRAOCULAR PRESSURE | ALCON LABORATORIES, INC. (US) | 1995-01-03 | — | — | US | disclosed |
| US-5240923-A | Treating glaucoma | ALCON LABORATORIES, INC. (US) | 1993-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141412-A1 | PRODUCTION OF STERILE ACTIVE PHARMACEUTICAL INGREDIENTS | AP3S1, ALPG, LSS | CA2 2669/4885CA4 2368/4885CA12 3290/4885 |
| US-20210145836-A1 | PRODUCTION OF STERILE ACTIVE PHARMACEUTICAL INGREDIENTS | AP3S1, ALPG, LSS | CA2 2669/4885CA4 2368/4885CA12 3290/4885 |
| US-10953115-B2 | Production of sterile active pharmaceutical ingredients | AP3S1, ALPG, LSS | CA2 2669/4885CA4 2368/4885CA12 3290/4885 |
| US-20110118461-A1 | PROCESS FOR THE PREPARATION OF BRINZOLAMIDE | CYP3A4, CYP4B1, SULT1E1 | CA2 1003/4885CA4 327/4885CA12 3313/4885 |
| US-20170355966-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | AKR1C4, AKR7A2, AKR1C2 | CA2 4818/4885CA4 4431/4885CA12 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.